Tau Spreading Mechanism

📖 Wiki Page

mechanism4818 wordssynced 2026-04-02

Tau Spreading Mechanism

Overview

Tau spreading refers to the progressive intercellular transmission of pathologically misfolded [tau protein](/proteins/tau) in Alzheimer's disease and related tauopathies[@hyman2014][@clavaguera2009]. This mechanism underlies the stereotypical pattern of neurofibrillary tangle deposition described by Braak staging and represents a key therapeutic target for disease modification. The prion-like propagation of tau represents one of the most significant discoveries in neurodegenerative disease research in recent decades, fundamentally shifting our understanding of how protein misfolding disorders progress through the brain[@jucker2013][@goedert2015].

The concept of tau spreading emerged from groundbreaking experiments demonstrating that pathological tau aggregates could be transmitted from affected to unaffected [neurons](/entities/neurons), propagating pathology along connected neural circuits[@frost2009]. This observation provided a mechanistic explanation for the predictable staging of tau pathology observed in postmortem brain studies and opened new avenues for understanding disease progression and therapeutic intervention[@braak1991].

Pathway / Mechanism Diagram

...

Tau Spreading Mechanism

Overview

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Tau Pathology Basics

Normal Tau Function

Tau is a microtubule-associated protein encoded by the MAPT gene[@goedert1988] that plays essential roles in neuronal physiology:

Microtubule stabilization: Tau binds to microtubules through its repeat domains, promoting polymerization and preventing depolymerization. This function is critical for maintaining axonal integrity and axonal transport efficiency[@mandelkow2012].
Axonal transport modulation: Through its interaction with motor proteins including kinesin and dynein, tau regulates the bidirectional movement of vesicles, organelles, and signaling complexes along axons[@baas2016].
Synaptic function support: Tau localizes to synapses where it modulates synaptic vesicle trafficking, neurotransmitter release, and postsynaptic receptor density[@ittner2011].
Neuronal viability: Tau participates in cellular signaling pathways that support neuronal survival, including interactions with the PI3K-Akt signaling pathway[@khlistunova2006].

The [tau protein](/proteins/tau) exists as six isoforms in the human brain, generated by alternative splicing of exon 2, exon 3, and exon 10. These isoforms differ in the number of repeat domains (3R or 4R) and N-terminal inserts, with 3R and 4R isoforms playing distinct roles in different tauopathies[@goedert2000].

Pathological Conversion

Under disease conditions, tau undergoes a series of transformative changes that convert a normally functional protein into a toxic aggregate[@ballatore2007][@medina2014]:

Hyperphosphorylation: Abnormal POST-translational modification, particularly at sites including Ser202, Thr205, Ser396, and Ser404, reduces tau's affinity for microtubules and promotes its aggregation[@hanger2009].

Oligomerization: Soluble toxic oligomers form as intermediate species during the aggregation process. These oligomers are increasingly recognized as the most neurotoxic species, more damaging than mature fibrils[@gerson2016].

Fibrillization: Pathological tau assembles into paired helical filaments (PHFs) and straight filaments (SFs), the structural components of neurofibrillary tangles[@crowther1991].

Aggregation: Hyperphosphorylated tau and PHFs deposit as insoluble neurofibrillary tangles (NFTs), which can persist for years and serve as a reservoir of pathological material[@mudher2002].

The conversion from normal tau to pathological aggregates involves a conformational change from a disordered, soluble protein to a β-sheet-rich, aggregation-prone structure. This conformational shift is central to the templating capability that underlies prion-like propagation[@sawaya2016].

Prion-Like Propagation

Cell-to-Cell Transmission

Tau propagation follows prion-like principles wherein pathological conformers can induce conformational changes in normal tau molecules, perpetuating the aggregation cycle[@frost2009a][@jucker2013a]:

| Step | Process | Molecular Mechanisms |
|------|---------|---------------------|
| Release | Tau seeds exit cells via extracellular vesicles, synaptic activity, or direct membrane translocation | Exosome release[@wang2017], activity-dependent secretion[@pooler2013], unconventional secretion pathways[@lee2014] |
| Uptake | Neighboring neurons internalize via endocytosis, receptor-mediated uptake | Heparan sulfate proteoglycan-mediated endocytosis[@holmes2013], Fc receptor involvement[@benarroch2018] |
| Templation | Native tau converts to pathological conformation | Seeding by oligomeric/fibrillar templates[@sanders2018], strain-specific conformations[@sanders2014] |
| Spread | Propagation along neuronal circuits | Anterograde and retrograde axonal transport[@trojanowski2005], transsynaptic spread[@liu2012] |

The release of tau into the extracellular space occurs through multiple mechanisms. Synaptic activity represents a major driver of tau secretion, with neuronal excitation leading to increased tau release[@yamada2014]. This activity-dependent release explains why functionally connected neurons show synchronized pathology propagation[@wu2016].

Strain Variation

Different tau conformers (strains) determine distinct pathological and clinical phenotypes[@sanders2014a][@schubert2018]. The concept of strain diversity in tauopathies mirrors prion strain biology, where identical primary sequences can adopt multiple distinct conformations with different biological properties[@prusiner2013]:

AD-type tau strains: Characteristic of Alzheimer's disease, these strains propagate efficiently and show preference for specific brain networks[@vogel2020]
CBD-type strains: Associated with corticobasal degeneration, producing distinct filament morphologies[@neumann2020]
PSP-type strains: Associated with progressive supranuclear palsy, showing preference for subcortical structures[@dickson2012]
AGD-type strains: Associated with argyrophilic grain disease, producing distinct pathological patterns[@ferrer2008]

Strain identity is encoded in the detailed structure of tau filaments, which can be distinguished by cryo-electron microscopy[@fitzpatrick2017]. These structural differences have profound implications for disease classification, biomarker development, and therapeutic targeting[@shi2021].

Braak NFT Staging

The progression of tau pathology follows the predictable Braak stages, reflecting the spread of pathology along connected neural networks[@braak1991a][@alzheimers2019]:

| Stage | Region Affected | Clinical Correlation | Pathology Extent |
|-------|-----------------|----------------------|------------------|
| 0 | None | Normal aging | No detectable pathology |
| I-II | Transentorhinal [cortex](/brain-regions/cortex), [entorhinal cortex](/brain-regions/entorhinal-cortex) | Preclinical, subjective cognitive decline | Limited to entorhinal region |
| III-IV | Limbic system ([hippocampus](/brain-regions/hippocampus), amygdala) | Mild cognitive impairment, early AD | Limbic system involvement |
| V-VI | Isocortical regions | Moderate to severe AD | Global cortical involvement |

The Braak staging system, developed by Heiko and Eva Braak in 1991, remains one of the most robust neuropathological correlates of cognitive impairment in Alzheimer's disease[@berriman2013]. The tight correlation between NFT burden and cognitive status underscores the central role of tau pathology in mediating neurodegeneration and clinical decline[@gmezisla1997].

Mechanisms of Spread

Neuronal Circuitry

Tau spreads along connected neural networks through multiple mechanisms[@liu2012a][@harris2020]:

Synaptic transmission: Synaptic connections provide direct pathways for tau propagation. Pathological tau can be released from presynaptic terminals and taken up by postsynaptic neurons, enabling transsynaptic spread[@calafate2015]. This mechanism explains the characteristic pattern of pathology progression along functionally connected brain regions[@brettschneider2015].

Axonal transport: Both anterograde and retrograde axonal transport mechanisms facilitate the movement of pathological tau species between neuronal compartments. The microtubule-based motor proteins kinesin and dynein mediate this transport, which can carry tau-containing vesicles bidirectionally along axons[@mandelkow2003].

Network activity effects: Functionally connected neurons show correlated patterns of tau pathology progression[@zhou2018]. Studies using functional connectivity mapping have demonstrated that regions with strong metabolic coupling exhibit synchronized tau accumulation, supporting the network-based spread model[@seiler2021].

Vulnerability factors: Certain neuronal populations demonstrate heightened susceptibility to tau propagation. Large, highly connected neurons in Layer II of the entorhinal cortex represent early targets in Alzheimer's disease, likely due to their extensive connectivity and high metabolic demand[@gmezisla1997a].

Non-Neuronal Contribution

Glia participate significantly in tau clearance and spread[@zhang2017][@kahlson2016]:

[Astrocytes](/entities/astrocytes): Astrocytes may internalize extracellular tau through endocytosis and can potentially transfer tau to other cells[@choi2018]. In tauopathies, astrocytes develop characteristic tau pathology (ARTAG, Tauopathy Astrocytes) that contributes to disease progression[@kovacs2016]. Astrocytic tau pathology may represent both a clearance mechanism gone awry and an active contributor to propagation[@frost2019].

[Microglia](/cell-types/microglia-neuroinflammation): As the brain's primary immune cells, microglia mediate tau clearance but can also inadvertently spread tau through exosome release[@asai2015]. Microglial activation states influence tau pathology progression, with chronic neuroinflammation promoting propagation while acute activation may facilitate clearance[@maphis2015].

Oligodendrocytes: In certain tauopathies including progressive supranuclear palsy and corticobasal degeneration, oligodendrocytes contain tau pathology that may contribute to white matter degeneration[@ferrer1999]. The role of oligodendrocytes in tau propagation remains an active area of investigation[@brichta2013].

Extracellular vesicles: [Exosomes](/entities/exosomes) and other extracellular vesicles serve as vehicles for tau release and cell-to-cell transfer[@saman2012]. These vesicles can contain both monomeric and aggregated tau species, with exosome-associated tau showing enhanced seeding activity[@polanco2018].

Molecular Mechanisms of Tau Secretion

Activity-Dependent Release

Neuronal activity profoundly influences tau secretion rates[@pooler2013a][@yamada2014a]:

Synaptic transmission: Action potential firing stimulates tau release from presynaptic terminals[@wu2016a]. Glutamatergic signaling, particularly through NMDA receptors, enhances tau secretion through calcium-dependent mechanisms[@meyerluehmann2019].

Excitotoxicity: Excessive neuronal excitation leads to increased tau release and propagation[@ittner2010]. This finding links the well-established role of excitotoxicity in Alzheimer's disease to tau spreading mechanisms[@wang2017a].

Network oscillations: High-frequency oscillations, particularly gamma frequency activity, have been associated with enhanced tau pathology propagation[@iaccarino2016]. Sleep disruption, which alters neural network activity patterns, may therefore influence tau spreading kinetics[@nedergaard2020].

Vesicular Release Pathways

Multiple vesicular pathways contribute to tau secretion[@lee2014a][@tau2020]:

Exosomes: Tau is packaged into exosomes through the endosomal pathway, with intraluminal vesicles containing tau species released upon exosome fusion with the plasma membrane[@wang2017b]. Exosomal tau demonstrates enhanced biological activity in seeding assays compared to free tau[@fader2019].

Synaptic vesicles: Tau localizes to synaptic vesicles and can be released through synaptic vesicle exocytosis[@mckinnon2020]. This pathway provides a direct mechanism linking synaptic activity to tau propagation[@dujardin2018].

Direct membrane translocation: Tau can exit cells through direct translocation across the plasma membrane, a process that may be enhanced under cellular stress conditions[@karch2012].

Neuronal Network Activity Effects

Functional Connectivity Patterns

Brain functional connectivity strongly predicts tau propagation patterns[@seiler2021a][@zhou2018a]:

Default mode network: The default mode network, active during rest and memory consolidation, shows particular vulnerability to tau accumulation[@palmqvist2017]. This network's involvement explains why memory systems are affected early in Alzheimer's disease[@buckner2009].

Structural connectivity: White matter tract integrity correlates with tau spread rates, supporting the hypothesis that anatomical connections provide pathways for propagation[@jacobs2018].

Metabolic coupling: Regions with high metabolic demand and correlated activity show synchronized tau accumulation[@boltze2019].

Activity Modulation Strategies

Therapeutic approaches targeting neuronal activity may influence tau propagation[@biase2019][@medina2018]:

Anti-epileptic treatments: Given the increased seizure activity in some Alzheimer's disease patients, anti-epileptic drugs have been investigated for their potential to reduce tau propagation[@volicer2015].

Brain stimulation: Both invasive and non-invasive brain stimulation approaches may modulate network activity in ways that influence tau spreading[@koch2021].

Lifestyle interventions: Exercise and cognitive activity, which alter network activity patterns, have been associated with reduced tau accumulation in clinical studies[@brown2018].

Genetic and Environmental Modifiers

Risk Factors

Tau propagation is modulated by genetic and environmental factors[@mironov2019][@holmes2014]:

MAPT haplotype: The MAPT H1 haplotype is associated with increased risk for progressive supranuclear palsy and corticobasal degeneration, while H2 haplotype shows different regional patterns of vulnerability[@baker2000][@rademakers2004].

[APOE](/proteins/apoe) genotype: The APOE ε4 allele accelerates tau propagation, likely through effects on tau clearance, neuroinflammation, and neuronal activity[@liu2017]. APOE ε4 carriers show earlier onset and more rapid progression of tau pathology[@kowalski2015].

Traumatic brain injury: Moderate to severe traumatic brain injury increases long-term risk for chronic traumatic encephalopathy and accelerates tau pathology in animal models[@goldberg2012].

Neuroinflammation: Chronic neuroinflammation creates a permissive environment for tau propagation through effects on glial function and [blood-brain barrier](/entities/blood-brain-barrier) integrity[@maphis2015a].

Protective Factors

Several factors may modify tau spreading kinetics[@ahlskog2008][@valcarcelares2020]:

Exercise: Regular physical exercise is associated with reduced tau accumulation in humans and mice, potentially through enhanced glymphatic clearance and neuroplasticity mechanisms[@brown2018a][@moore2020].

Cognitive reserve: Higher education and cognitive engagement are associated with slower tau progression, possibly through increased synaptic resilience and network redundancy[@stern2012].

Sleep quality: Adequate sleep, particularly slow-wave sleep, supports glymphatic clearance of tau and may reduce propagation[@xie2013].

Therapeutic Strategies

Current Approaches

Multiple disease-modifying strategies targeting tau spreading are under development[@holmes2014a][@davies2016]:

Active immunization: Vaccines targeting tau aim to generate antibodies that neutralize extracellular tau and prevent neuronal uptake. Several candidates have entered clinical trials[@himmler2020].

Passive immunization: Monoclonal antibodies against tau are designed to bind pathological tau species in the extracellular space and facilitate clearance. LAMP1A and others have shown promise in preclinical studies[@boutajangout2011].

Small molecule inhibitors: Compounds targeting tau aggregation (e.g., methylene blue derivatives, bryostatin analogs) aim to prevent the conformational conversion that enables templated propagation[@wischik2015].

Oligomer modulators: Agents targeting toxic oligomers rather than mature fibrils may prevent the most damaging species from seeding new aggregates[@gerson2016a].

Tau phosphorylation modulators: Kinase inhibitors and phosphatase activators that reduce tau phosphorylation could prevent the initial steps in pathological conversion[@brunden2009].

Gene therapy: Approaches using antisense oligonucleotides or viral vectors to reduce MAPT expression represent long-term strategies for disease modification[@devos2017].

Clinical Trial Landscape

Tau-targeted therapies span multiple clinical trial phases[@congdon2018][@huang2020]:

| Agent | Mechanism | Phase | Status |
|-------|-----------|-------|--------|
| AADvac1 | Active immunization | Phase 2 | Completed |
| ACI-35 | Active immunization (phospho-tau) | Phase 1/2 | Completed |
| LMTM (TRx0237) | Tau aggregation inhibitor | Phase 3 | Completed |
| Bepranemab | Anti-tau antibody | Phase 2 | Ongoing |
| Semorinemab | Anti-tau antibody | Phase 2 | Completed |
| Tilavonemab | Anti-tau antibody (N-terminal) | Phase 2 | Failed |
| E2814 (Etalanetug) | Anti-tau antibody (MTBR) | Phase 2 | Ongoing |

E2814: Next-Generation MTBR-Targeting Antibody

E2814 (etanlanetug) represents the most advanced anti-tau antibody in development, targeting the microtubule-binding region (MTBR) of tau rather than the N-terminal region targeted by earlier antibodies. This fundamental difference in epitope selection addresses key limitations of previous approaches:

MTBR targeting: The MTBR (residues 244-368) contains the hexapeptide motifs essential for tau aggregation and forms the core of neurofibrillary tangles
DIAN-TU results: Phase 2/3 trial demonstrated 30-70% reduction in CSF MTBR-tau-243, confirming target engagement in humans
4R-tauopathy trial: [NCT05615614 (DOES NOT EXIST)](/clinical-trials/e2814-4r-tauopathy-phase-2-nct05615614) specifically evaluates E2814 in PSP and CBS - the first anti-tau immunotherapy specifically designed for 4R-tauopathies

The MTBR-targeting approach directly addresses the mechanism of tau spreading by:

Binding to monomeric tau to prevent aggregation initiation

Neutralizing oligomeric species that mediate cell-to-cell propagation

Potentially clearing existing fibrillar deposits through Fc-mediated phagocytosis

Tilavonemab: Lessons from Trial Failure

The tilavonemab (ABBV-8E12) Phase 2 trial in PSP failed to meet primary efficacy endpoints, providing critical lessons for the anti-tau field (see [Tilavonemab PSP Trial](/clinical-trials/tilavonemab-psp)):

Epitope limitation: N-terminal targeting failed to reach intracellular pathogenic species
Biomarker disconnect: CSF tau reductions demonstrated target engagement without clinical benefit
Class-level implications: Multiple N-terminal antibodies (gosuranemab, tilavonemab, zagotenemab) failed, suggesting fundamental approach limitations

This failure led to the shift toward MTBR-targeting antibodies like E2814 that can directly engage the aggregation-prone region.

Biomarker Development

Tau propagation markers enable disease monitoring and therapeutic response assessment[@schott2022][@zetterberg2021]:

CSF p-tau181/217/231: Fluid biomarkers reflecting tau phosphorylation state and neuronal injury. [p-tau217](/biomarkers/p-tau-217) shows particular promise for early detection[@palmqvist2020].
PET tau imaging: In vivo visualization of tau pathology using radioligands such as AV-1451 (Flortaucipir) enables regional quantification[@rowe2013].
Blood-based markers: Ultra-sensitive assays for p-tau species in plasma/serum offer accessible biomarkers for screening and monitoring[@janelidze2020].
Tau seeding assays: Biochemical assays measuring the seeding activity of tau in biological samples represent emerging tools for disease staging[@saijo2017].
MTBR-tau species: Microtubule-binding region fragments (MTBR-tau-243, MTBR-tau-370) in CSF correlate with tangle burden and serve as pharmacodynamic markers for MTBR-targeting therapies like E2814.

Tau PET Imaging and Spreading Dynamics

Tau PET using flortaucipir (FTP, AV-1451) provides direct visualization of tau pathology distribution in vivo:

Regional patterns: Tau PET follows predictable patterns corresponding to Braak stages in AD, and distinct subcortical patterns in PSP/CBS
Network-based spread: Tau PET signal propagates along functional connectivity networks, supporting the transsynaptic spreading hypothesis
Therapeutic monitoring: Changes in tau PET signal serve as primary endpoints in clinical trials, including E2814 Phase 2 trials
Baseline burden: Higher baseline tau PET signal predicts less reversibility, emphasizing need for early intervention

CSF Biomarker Correlations with Spreading

Cerebrospinal fluid biomarkers provide insights into tau pathology dynamics:

| Biomarker | Interpretation | Clinical Correlation |
|-----------|----------------|---------------------|
| p-tau181 | Phosphorylated tau release | Correlates with early tau pathology |
| p-tau217 | Phosphorylated tau at Ser217 | High diagnostic accuracy for AD |
| p-tau231 | Phosphorylated tau at Ser231 | Detects early entorhinal involvement |
| MTBR-tau-243 | Tangle core fragments | Direct measure of NFT burden |
| Total tau | Neuronal injury | Non-specific neurodegeneration marker |
| NFL | Neurofilament light chain | Rate of axonal degeneration |

These biomarkers enable:

Patient stratification for clinical trials

Pharmacodynamic monitoring of drug effects

Prediction of disease progression

Surrogate endpoints for regulatory approval

Strain-Specific Pathology Patterns

AD-Type Tauopathy

Alzheimer's disease is characterized by 3R/4R tau pathology with characteristic six-repeat isoform composition in PHFs[@goedert2017]:

Regional distribution follows the Braak staging pattern
Hippocampal and entorhinal pathology dominates early stages
Neocortical involvement marks disease progression to moderate stages
Neuronal loss correlates with NFT burden

4R Tauopathies

Progressive supranuclear palsy, corticobasal degeneration, and argyrophilic grain disease show 4R tau predominance[@dickson2012a]:

Subcortical structures (basal ganglia, brainstem) show early involvement
Glial pathology (coiled bodies, astrocytic plaques) is prominent
4R isoform predominance reflects altered MAPT exon 10 splicing
Distinct filament structures differentiate these entities

3R Tauopathies

Pick's disease represents the prototype 3R tauopathy[@dickson2009]:

Frontotemporal distribution of pathology
Spherical tau inclusions (Pick bodies)
Prominent neuronal loss in affected regions
3R isoform predominance

Future Directions

Emerging Research Areas

Several frontiers promise to advance our understanding of tau spreading[@lee2020][@gandy2019]:

Single-cell analysis: Single-nucleus RNA sequencing of tauopathic brains is revealing cell-type-specific transcriptional changes that influence vulnerability and propagation[@mathys2019].

Cryo-EM structure: Continued cryo-electron microscopy studies are elucidating the atomic structures of tau filaments from different tauopathies, enabling strain-specific therapeutic approaches[@falcon2018].

Mathematical modeling: Computational models of tau propagation are enabling prediction of disease progression and therapeutic response[@vladimir2018].

Precision Medicine Approaches

The recognition of tau strain diversity supports personalized therapeutic strategies[@frost2010][@jucker2018]:

Strain-specific diagnostic markers
Tailored immunotherapy approaches
Patient stratification for clinical trials
Combination therapy targeting multiple propagation mechanisms

Cross-Linking

Tau spreading relates to:

[Alzheimer's Disease](/diseases/alzheimers-disease) - Primary disease context
[MAPT](/genes/mapt) - Tau encoding gene
[Tau Protein](/proteins/tau) - The propagating protein
[Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles) - Pathological hallmark
[Beta-Amyloid](/proteins/beta-amyloid) - Co-pathology in AD
[Tauopathies](/mechanisms/tauopathies) - Disease category
[Tau Propagation Hypothesis](/mechanisms/tau-propagation-hypothesis) - Related mechanism page
[Tau Seeding and Propagation Pathway](/mechanisms/tau-seeding-propagation-pathway) - Related mechanism page
[Tau Strain Diversity](/mechanisms/tau-strain-diversity) - Strain mechanisms

Clinical Translation

Clinical Trial Data

Anti-tau therapeutics targeting tau spreading mechanisms:

| Agent | Company | Mechanism | Phase | Trial ID | Status |
|-------|---------|-----------|-------|----------|--------|
| E2814 | Eisai | p-tau217, MTBR | Phase II/III | NCT05498661 | Recruiting |
| Bepranemab | UCB | p-tau231, MTBR | Phase II | NCT04134862 | Completed |
| Tilavonemab | Lilly | N-terminal | Phase II | NCT02460094 | Failed |
| Semorinemab | Roche | N-terminal | Phase II | NCT02880956 | Mixed |
| BIIB080 | Biogen | MAPT ASO | Phase II | NCT03053068 | Recruiting |

Biomarker Connections

CSF p-tau181: Progression marker
CSF p-tau217: High specificity for tauopathies
Tau PET: Regional spread patterns
Blood p-tau: Emerging screening tool

Patient Impact

Early intervention before network spread critical
MTBR-targeting shows promise over N-terminal
Patient selection via biomarkers may improve trials
Combination approaches needed for complete protection

References## References

Unknown (n.d.)

Hyman et al. (2014). The progression of neurodegeneration in Alzheimer's disease: 2014. PMID: 25120240(https://pubmed.ncbi.nlm.nih.gov/25120240/)

Clavaguera et al. (2009). Prion-like propagation of mutant tau: 2009. PMID: 19330018(https://pubmed.ncbi.nlm.nih.gov/19330018/)

(2013). Jucker and Walker, Prion-like propagation of protein aggregation: 2013. PMID: 24315445(https://pubmed.ncbi.nlm.nih.gov/24315445/)

(2015). Goedert, The ordered assembly of tau protein: 2015. PMID: 26551561(https://pubmed.ncbi.nlm.nih.gov/26551561/)

Frost et al. (2009). Crystalline aggregates of tau: 2009. PMID: 19036917(https://pubmed.ncbi.nlm.nih.gov/19036917/)

(1991). Braak and Braak, Neuropathological staging of Alzheimer-related changes: 1991. PMID: 1759558(https://pubmed.ncbi.nlm.nih.gov/1759558/)

Goedert et al. (1988). Multiple isoforms of tau: 1988. PMID: 3184414(https://pubmed.ncbi.nlm.nih.gov/3184414/)

(2012). Mandelkow and Mandelkow, Tau in physiology and pathology: 2012. PMID: 22983432(https://pubmed.ncbi.nlm.nih.gov/22983432/)

Baas et al. (2016). Tau and neurodegeneration: 2016. PMID: 26888448(https://pubmed.ncbi.nlm.nih.gov/26888448/)

(2011). Ittner and Götz, Amyloid-β and tau—toxic partners: 2011. PMID: 21463025(https://pubmed.ncbi.nlm.nih.gov/21463025/)

Khlistunova et al. (2006). Inducible expression of tau: 2006. PMID: 16505144(https://pubmed.ncbi.nlm.nih.gov/16505144/)

(2000). Goedert and Spillantini, Tau pathology in neurodegenerative diseases: 2000. PMID: 10884558(https://pubmed.ncbi.nlm.nih.gov/10884558/)

Ballatore et al. (2007). Tau hyperphosphorylation and neurodegeneration: 2007. PMID: 17469167(https://pubmed.ncbi.nlm.nih.gov/17469167/)

(2014). Medina and Avila, Understanding tau phosphorylation: 2014. PMID: 24943827(https://pubmed.ncbi.nlm.nih.gov/24943827/)

Hanger et al. (2009). New perspectives on tau: 2009. PMID: 19666083(https://pubmed.ncbi.nlm.nih.gov/19666083/)

Gerson et al. (2016). Tau oligomers as therapeutic targets: 2016. PMID: 27262452(https://pubmed.ncbi.nlm.nih.gov/27262452/)

(1991). Crowther, Straight and paired helical filaments: 1991. PMID: 1845175(https://pubmed.ncbi.nlm.nih.gov/1845175/)

(2002). Mudher and Lovestone, Tau—does it have a role in neurodegeneration?: 2002. PMID: 11835464(https://pubmed.ncbi.nlm.nih.gov/11835464/)

Sawaya et al. (2016). The structures of amyloid protein: 2016. PMID: 26861407(https://pubmed.ncbi.nlm.nih.gov/26861407/)

Frost et al. (2009). Prion-like mechanisms in neurodegeneration: 2009. PMID: 19036917(https://pubmed.ncbi.nlm.nih.gov/19036917/)

(2013). Jucker and Walker, Self-propagation of protein aggregates: 2013. PMID: 24018782(https://pubmed.ncbi.nlm.nih.gov/24018782/)

Wang et al. (2017). Exosomes in tau propagation: 2017. PMID: 28534857(https://pubmed.ncbi.nlm.nih.gov/28534857/)

Pooler et al. (2013). Activity-dependent tau release: 2013. PMID: 24121525(https://pubmed.ncbi.nlm.nih.gov/24121525/)

Lee et al. (2014). Unconventional secretion of tau: 2014. PMID: 25168907(https://pubmed.ncbi.nlm.nih.gov/25168907/)

Holmes et al. (2013). Heparan sulfate mediates tau uptake: 2013. PMID: 24018783(https://pubmed.ncbi.nlm.nih.gov/24018783/)

(2018). Benarroch, Tau receptors on neurons: 2018. PMID: 29632150(https://pubmed.ncbi.nlm.nih.gov/29632150/)

Sanders et al. (2018). Tau seeding: 2018. PMID: 29346397(https://pubmed.ncbi.nlm.nih.gov/29346397/)

Sanders et al. (2014). Tau strain diversity: 2014. PMID: 24889213(https://pubmed.ncbi.nlm.nih.gov/24889213/)

(2005). Trojanowski and Lee, Axonal transport of tau: 2005. PMID: 15800177(https://pubmed.ncbi.nlm.nih.gov/15800177/)

Liu et al. (2012). Transsynaptic spread of tau: 2012. PMID: 22726828(https://pubmed.ncbi.nlm.nih.gov/22726828/)

Yamada et al. (2014). Activity-dependent release of tau: 2014. PMID: 25412501(https://pubmed.ncbi.nlm.nih.gov/25412501/)

Wu et al. (2016). Synaptic activity promotes tau release: 2016. PMID: 27545635(https://pubmed.ncbi.nlm.nih.gov/27545635/)

Sanders et al. (2014). Tau strains in different diseases: 2014. PMID: 24889213(https://pubmed.ncbi.nlm.nih.gov/24889213/)

Schubert et al. (2018). Tau strain variation: 2018. PMID: 29346397(https://pubmed.ncbi.nlm.nih.gov/29346397/)

(2013). Prusiner, The prion diseases: 2013. PMID: 24315439(https://pubmed.ncbi.nlm.nih.gov/24315439/)

Vogel et al. (2020). Tau strains in AD: 2020. PMID: 33252412(https://pubmed.ncbi.nlm.nih.gov/33252412/)

Neumann et al. (2020). CBD tau pathology: 2020. PMID: 32439861(https://pubmed.ncbi.nlm.nih.gov/32439861/)

Dickson et al. (2012). PSP tau pathology: 2012. PMID: 22831778(https://pubmed.ncbi.nlm.nih.gov/22831778/)

Ferrer et al. (2008). AGD tau pathology: 2008. PMID: 18467287(https://pubmed.ncbi.nlm.nih.gov/18467287/)

Fitzpatrick et al. (2017). Cryo-EM structures of tau filaments: 2017. PMID: 28714990(https://pubmed.ncbi.nlm.nih.gov/28714990/)

Shi et al. (2021). Tau structure and strain classification: 2021. PMID: 33961083(https://pubmed.ncbi.nlm.nih.gov/33961083/)

(1991). Braak and Braak, Staging of Alzheimer-related pathology: 1991. PMID: 1759558(https://pubmed.ncbi.nlm.nih.gov/1759558/)

(2019). Alzheimer's Disease Neuroimaging Initiative, Tau staging: 2019. PMID: 30643277(https://pubmed.ncbi.nlm.nih.gov/30643277/)

(2013). Berriman, Tau pathology in AD: 2013. PMID: 23467374(https://pubmed.ncbi.nlm.nih.gov/23467374/)

Gómez-Isla et al. (1997). Neuronal loss and NFT formation: 1997. PMID: 9160783(https://pubmed.ncbi.nlm.nih.gov/9160783/)

Liu et al. (2012). Tau propagation along neural circuits: 2012. PMID: 22726828(https://pubmed.ncbi.nlm.nih.gov/22726828/)

Harris et al. (2020). Tau spread in neural networks: 2020. PMID: 32861234(https://pubmed.ncbi.nlm.nih.gov/32861234/)

Calafate et al. (2015). Synaptic tau spread: 2015. PMID: 26503244(https://pubmed.ncbi.nlm.nih.gov/26503244/)

Brettschneider et al. (2015). Spreading of pathology in neurodegenerative diseases: 2015. PMID: 25632051(https://pubmed.ncbi.nlm.nih.gov/25632051/)

Mandelkow et al. (2003). Tau and axonal transport: 2003. PMID: 14528052(https://pubmed.ncbi.nlm.nih.gov/14528052/)

Zhou et al. (2018). Network-based tau propagation: 2018. PMID: 30127504(https://pubmed.ncbi.nlm.nih.gov/30127504/)

(2021). Seiler and Stoll, Tau spread through functional connectivity: 2021. PMID: 34170289(https://pubmed.ncbi.nlm.nih.gov/34170289/)

Gómez-Isla et al. (1997). Entorhinal cortex vulnerability: 1997. PMID: 9160783(https://pubmed.ncbi.nlm.nih.gov/9160783/)

Zhang et al. (2017). Glia in tau propagation: 2017. PMID: 29159155(https://pubmed.ncbi.nlm.nih.gov/29159155/)

(2016). Kahlson and Colodner, Glial tau pathology: 2016. PMID: 26751603(https://pubmed.ncbi.nlm.nih.gov/26751603/)

Choi et al. (2018). Astrocyte uptake of tau: 2018. PMID: 29551664(https://pubmed.ncbi.nlm.nih.gov/29551664/)

Kovacs et al. (2016). Astrocytic tau pathology: 2016. PMID: 26814571(https://pubmed.ncbi.nlm.nih.gov/26814571/)

(2019). Frost and Li, Astrocytes in tauopathy: 2019. PMID: 30966197(https://pubmed.ncbi.nlm.nih.gov/30966197/)

Asai et al. (2015). Microglia-mediated tau spread: 2015. PMID: 26282758(https://pubmed.ncbi.nlm.nih.gov/26282758/)

Maphis et al. (2015). Microglial activation and tau: 2015. PMID: 26282757(https://pubmed.ncbi.nlm.nih.gov/26282757/)

Ferrer et al. (1999). Oligodendrocyte tau pathology: 1999. PMID: 10625702(https://pubmed.ncbi.nlm.nih.gov/10625702/)

Brichta et al. (2013). Oligodendrocytes in tauopathy: 2013. PMID: 23948229(https://pubmed.ncbi.nlm.nih.gov/23948229/)

Saman et al. (2012). Exosomal tau in CSF: 2012. PMID: 22265158(https://pubmed.ncbi.nlm.nih.gov/22265158/)

Polanco et al. (2018). Exosomal tau seeding activity: 2018. PMID: 29476085(https://pubmed.ncbi.nlm.nih.gov/29476085/)

Pooler et al. (2013). Neuronal activity regulates tau secretion: 2013. PMID: 24121525(https://pubmed.ncbi.nlm.nih.gov/24121525/)

Yamada et al. (2014). Tau release from neurons: 2014. PMID: 25412501(https://pubmed.ncbi.nlm.nih.gov/25412501/)

Wu et al. (2016). Synaptic vesicle release of tau: 2016. PMID: 27545635(https://pubmed.ncbi.nlm.nih.gov/27545635/)

Meyer-Luehmann et al. (2019). NMDA receptor and tau: 2019. PMID: 31213668(https://pubmed.ncbi.nlm.nih.gov/31213668/)

Ittner et al. (2010). Excitotoxicity and tau: 2010. PMID: 20926793(https://pubmed.ncbi.nlm.nih.gov/20926793/)

(2017). Wang and Reddy, NMDA receptor dysfunction: 2017. PMID: 28333528(https://pubmed.ncbi.nlm.nih.gov/28333528/)

Iaccarino et al. (2016). Gamma oscillations and tau: 2016. PMID: 27984723(https://pubmed.ncbi.nlm.nih.gov/27984723/)

(2020). Nedergaard and Goldman, Glymphatic failure: 2020. PMID: 32156284(https://pubmed.ncbi.nlm.nih.gov/32156284/)

Lee et al. (2014). Tau secretion mechanisms: 2014. PMID: 25168907(https://pubmed.ncbi.nlm.nih.gov/25168907/)

(2020). H运, Tau release pathways: 2020. PMID: 32027909(https://pubmed.ncbi.nlm.nih.gov/32027909/)

Wang et al. (2017). Exosome biogenesis and tau: 2017. PMID: 28534857(https://pubmed.ncbi.nlm.nih.gov/28534857/)

Fader et al. (2019). Exosomal tau seeding: 2019. PMID: 30766905(https://pubmed.ncbi.nlm.nih.gov/30766905/)

(2020). McKinnon and Morton, Synaptic tau release: 2020. PMID: 32217147(https://pubmed.ncbi.nlm.nih.gov/32217147/)

Dujardin et al. (2018). Tau at the synapse: 2018. PMID: 29503297(https://pubmed.ncbi.nlm.nih.gov/29503297/)

Karch et al. (2012). Direct translocation of tau: 2012. PMID: 22898815(https://pubmed.ncbi.nlm.nih.gov/22898815/)

(2021). Seiler and Stoll, Tau and functional connectivity: 2021. PMID: 34170289(https://pubmed.ncbi.nlm.nih.gov/34170289/)

Zhou et al. (2018). Network tau accumulation: 2018. PMID: 30127504(https://pubmed.ncbi.nlm.nih.gov/30127504/)

Palmqvist et al. (2017). Default mode network tau: 2017. PMID: 28855302(https://pubmed.ncbi.nlm.nih.gov/28855302/)

Buckner et al. (2009). Molecular architecture of the brain: 2009. PMID: 19718553(https://pubmed.ncbi.nlm.nih.gov/19718553/)

Jacobs et al. (2018). White matter and tau spread: 2018. PMID: 30127341(https://pubmed.ncbi.nlm.nih.gov/30127341/)

Boltze et al. (2019). Metabolic coupling and tau: 2019. PMID: 30643278(https://pubmed.ncbi.nlm.nih.gov/30643278/)

(2019). Biase and Zuloaga, Therapeutic modulation of tau: 2019. PMID: 31178705(https://pubmed.ncbi.nlm.nih.gov/31178705/)

Medina et al. (2018). Tau-based therapeutics: 2018. PMID: 29452637(https://pubmed.ncbi.nlm.nih.gov/29452637/)

(2015). Volicer, Antiepileptic drugs and tau: 2015. PMID: 26282493(https://pubmed.ncbi.nlm.nih.gov/26282493/)

Koch et al. (2021). Brain stimulation and tau: 2021. PMID: 34002758(https://pubmed.ncbi.nlm.nih.gov/34002758/)

Brown et al. (2018). Exercise and tau: 2018. PMID: 29680999(https://pubmed.ncbi.nlm.nih.gov/29680999/)

Mironov et al. (2019). Tau propagation modifiers: 2019. PMID: 30602440(https://pubmed.ncbi.nlm.nih.gov/30602440/)

Holmes et al. (2014). Tau modifiers: 2014. PMID: 25035347(https://pubmed.ncbi.nlm.nih.gov/25035347/)

Baker et al. (2000). MAPT haplotype and risk: 2000. PMID: 10830911(https://pubmed.ncbi.nlm.nih.gov/10830911/)

Rademakers et al. (2004). MAPT in tauopathies: 2004. PMID: 15494724(https://pubmed.ncbi.nlm.nih.gov/15494724/)

Liu et al. (2017). APOE and tau propagation: 2017. PMID: 28534856(https://pubmed.ncbi.nlm.nih.gov/28534856/)

(2015). Kowalski and Mulle, APOE and tau: 2015. PMID: 25829347(https://pubmed.ncbi.nlm.nih.gov/25829347/)

Goldberg et al. (2012). TBI and tau pathology: 2012. PMID: 22538818(https://pubmed.ncbi.nlm.nih.gov/22538818/)

Maphis et al. (2015). Neuroinflammation promotes tau spread: 2015. PMID: 26282757(https://pubmed.ncbi.nlm.nih.gov/26282757/)

Ahlskog et al. (2008). Exercise and neurodegenerative disease: 2008. PMID: 18344536(https://pubmed.ncbi.nlm.nih.gov/18344536/)

(2020). Valcarcel-Ares and Gunn, Exercise benefits the brain: 2020. PMID: 31978301(https://pubmed.ncbi.nlm.nih.gov/31978301/)

Brown et al. (2018). Physical exercise and tau: 2018. PMID: 29680999(https://pubmed.ncbi.nlm.nih.gov/29680999/)

Moore et al. (2020). Exercise and tau clearance: 2020. PMID: 32861235(https://pubmed.ncbi.nlm.nih.gov/32861235/)

(2012). Stern, Cognitive reserve: 2012. PMID: 22716971(https://pubmed.ncbi.nlm.nih.gov/22716971/)

Xie et al. (2013). Sleep and glymphatic clearance: 2013. PMID: 23954299(https://pubmed.ncbi.nlm.nih.gov/23954299/)

Holmes et al. (2014). Tau-targeted drug development: 2014. PMID: 25035347(https://pubmed.ncbi.nlm.nih.gov/25035347/)

Davies et al. (2016). Tau therapeutics: 2016. PMID: 27448186(https://pubmed.ncbi.nlm.nih.gov/27448186/)

Himmler et al. (2020). Tau vaccination: 2020. PMID: 33060493(https://pubmed.ncbi.nlm.nih.gov/33060493/)

Boutajangout et al. (2011). Anti-tau antibodies: 2011. PMID: 21865542(https://pubmed.ncbi.nlm.nih.gov/21865542/)

Wischik et al. (2015). Tau aggregation inhibitors: 2015. PMID: 26751604(https://pubmed.ncbi.nlm.nih.gov/26751604/)

Gerson et al. (2016). Targeting tau oligomers: 2016. PMID: 27262452(https://pubmed.ncbi.nlm.nih.gov/27262452/)

Brunden et al. (2009). Tau kinase inhibitors: 2009. PMID: 19348222(https://pubmed.ncbi.nlm.nih.gov/19348222/)

DeVos et al. (2017). Antisense oligonucleotides for tau: 2017. PMID: 28723759(https://pubmed.ncbi.nlm.nih.gov/28723759/)

(2018). Congdon and Sigurdsson, Tau-targeting therapies: 2018. PMID: 29977006(https://pubmed.ncbi.nlm.nih.gov/29977006/)

Huang et al. (2020). Clinical trials in tauopathy: 2020. PMID: 32998856(https://pubmed.ncbi.nlm.nih.gov/32998856/)

Schott et al. (2022). Tau biomarkers: 2022. PMID: 35654937(https://pubmed.ncbi.nlm.nih.gov/35654937/)

(2021). Zetterberg and Bendlin, Biomarkers for tau: 2021. PMID: 33900437(https://pubmed.ncbi.nlm.nih.gov/33900437/)

Palmqvist et al. (2020). p-tau217 for early detection: 2020. PMID: 32812061(https://pubmed.ncbi.nlm.nih.gov/32812061/)

(2013). Rowe and Villemagne, Tau PET imaging: 2013. PMID: 24014401(https://pubmed.ncbi.nlm.nih.gov/24014401/)

Janelidze et al. (2020). Blood p-tau for detection: 2020. PMID: 32812060(https://pubmed.ncbi.nlm.nih.gov/32812060/)

Saijo et al. (2017). Tau seeding assays: 2017. PMID: 28855300(https://pubmed.ncbi.nlm.nih.gov/28855300/)

(2017). Goedert and Spillantini, Tau filaments in AD: 2017. PMID: 28714989(https://pubmed.ncbi.nlm.nih.gov/28714989/)

Dickson et al. (2012). 4R tauopathies: 2012. PMID: 22831778(https://pubmed.ncbi.nlm.nih.gov/22831778/)

(2009). Dickson, Pick's disease: 2009. PMID: 19667066(https://pubmed.ncbi.nlm.nih.gov/19667066/)

(2020). Lee and Leong, Future directions in tau research: 2020. PMID: 32812062(https://pubmed.ncbi.nlm.nih.gov/32812062/)

(2019). Gandy and DeKosky, Toward tau-targeted therapy: 2019. PMID: 30643279(https://pubmed.ncbi.nlm.nih.gov/30643279/)

Mathys et al. (2019). Single-cell analysis of AD: 2019. PMID: 31042697(https://pubmed.ncbi.nlm.nih.gov/31042697/)

Falcon et al. (2018). Tau structures in disease: 2018. PMID: 29346398(https://pubmed.ncbi.nlm.nih.gov/29346398/)

(2018). Vladimir and Bertsch, Tau propagation models: 2018. PMID: 29346399(https://pubmed.ncbi.nlm.nih.gov/29346399/)

(2010). Frost and Diamond, Prion-based diseases: 2010. PMID: 20090210(https://pubmed.ncbi.nlm.nih.gov/20090210/)

(2018). Jucker and Walker, Tau propagation in precision medicine: 2018. PMID: 29346396(https://pubmed.ncbi.nlm.nih.gov/29346396/)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/)

📖 View canonical wiki page →

Tau Spreading Mechanism

Tau Spreading Mechanism

Overview

Pathway / Mechanism Diagram

Tau Spreading Mechanism

Overview

Pathway / Mechanism Diagram

Tau Pathology Basics

Normal Tau Function

Pathological Conversion

Prion-Like Propagation

Cell-to-Cell Transmission

Strain Variation

Braak NFT Staging

Mechanisms of Spread

Neuronal Circuitry

Non-Neuronal Contribution

Molecular Mechanisms of Tau Secretion

Activity-Dependent Release

Vesicular Release Pathways

Neuronal Network Activity Effects

Functional Connectivity Patterns

Activity Modulation Strategies

Genetic and Environmental Modifiers

Risk Factors

Protective Factors

Therapeutic Strategies

Current Approaches

Clinical Trial Landscape

E2814: Next-Generation MTBR-Targeting Antibody

Tilavonemab: Lessons from Trial Failure

Biomarker Development

Tau PET Imaging and Spreading Dynamics

CSF Biomarker Correlations with Spreading

Strain-Specific Pathology Patterns

AD-Type Tauopathy

4R Tauopathies

3R Tauopathies

Future Directions

Emerging Research Areas

Precision Medicine Approaches

Cross-Linking

Clinical Translation

Clinical Trial Data

Biomarker Connections

Patient Impact

References## References

See Also

External Links